Next-Generation Flagellin-Based Vaccines and Immunotherapies

The present inventive concept discloses a new generation of flagellin-based vaccines and immunotherapies that leverage advanced biotechnology tools, machine learning algorithms, and nanoparticle-based adjuvants to provide enhanced immune responses, personalized treatments, and targeted therapies against bacterial infections.

The original patent disclosed flagellin polypeptides from Enterococcus gallinarum for treating diseases, but it had limitations in terms of immune response stimulation, specificity, and adaptability to different bacterial strains. The present inventive concept addresses these limitations by introducing recombinant flagellin polypeptides with modified domains, nanoparticle-based adjuvants, and machine learning algorithms for personalized immunotherapy.

The new claims encompass a range of innovative approaches, including the use of recombinant flagellin polypeptides with engineered D0 domains for enhanced TLR5 recognition, personalized immunotherapy systems that utilize genomic information and machine learning algorithms to predict optimal flagellin polypeptide sequences, and modular platforms for developing flagellin-based vaccines with interchangeable modules for generating recombinant polypeptides and formulating them with various adjuvants and delivery systems.

The new claims introduce several novel and non-obvious elements, including the use of nanoparticle-based adjuvants, machine learning algorithms for personalized immunotherapy, and modular platforms for developing flagellin-based vaccines. These elements provide a significant departure from the original patent and offer a new generation of flagellin-based vaccines and immunotherapies with enhanced efficacy and adaptability.

Other embodiments of the inventive concept could include the use of different types of adjuvants, such as liposomes or emulsions, or alternative machine learning algorithms for predicting optimal flagellin polypeptide sequences. Additionally, the modular platform could be adapted for use with different bacterial strains or diseases, providing a flexible and scalable approach to vaccine development.

The present inventive concept has significant commercial potential in the vaccine and immunotherapy markets, particularly in the context of bacterial infections. The ability to provide personalized and targeted therapies could revolutionize the field of immunotherapy and provide new opportunities for pharmaceutical companies, biotechnology startups, and research institutions.